Benchmark Upgrades AbCellera to Buy with $11 Target on Major Jazz Pharmaceuticals Partnership
AbCellera gets a boost after Jazz deal brings upfront cash and future growth potential through cancer antibody programs and milestones.
/ 124 items
#XY Analyst Up/Down↓
Kyntra Bio Scores First Analyst Coverage: Oppenheimer Initiates Outperform with $35 Target
Kyntra Bio gains analyst support as its cancer drugs advance, with key Phase 2 data expected to drive future growth.
TD Cowen Boosts TransMedics Price Target to $120 on Strong Transplant Growth
Accelerating U.S. heart, liver & lung transplants plus strong flight data signal major growth ahead.
Replimune Stock Gets BMO Upgrade to Outperform as FDA De-Risks RP1 Approval
PDUFA date set for August 2, 2026.
Prime Medicine Gets Analyst Upgrade to Buy as First In Vivo Prime Editing Trial Moves Forward
H.C. Wainwright cites New Zealand clearance for PM577a — the first in vivo Prime Editing clinical trial for Wilson’s disease.
BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks
Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast.